Compare Mesoblast Limited (MESO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.87. The key difference: Mesoblast Limited is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| MESO | SJNK | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $25.63 |
52-Week Low | $12.88 | $24.75 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
SJNK trades at $24.87, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF shows consistent dividend distributions, with recent payouts of $0.14-$0.15. Institutional activity includes Cetera Investment Advisers reducing its position by 9.4% as of July 28, 2026, while news sentiment reflects caution on high-yield bonds.
The outlook remains cautious due to technical bearishness and negative media coverage, with risks from interest rate sensitivity and credit spreads. Investment appeal hinges on yield stability, but macroeconomic headwinds could pressure performance. Analysts highlight correlated vulnerabilities with broader junk bond ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
